
Gliminus M1
Each tablet contains:
Glimepiride……………….. ……………………………………1 mg
Metformuin Hydrochloride ……………………………….500mg
Gliminus M2
Each tablet contains:
Glimepiride……………….. ……………………………………2 mg
Metformuin Hydrochloride ……………………………….500mg
Tablet
Glimepiride primarily lowers blood glucose by stimulating the release of insulin from pancreatic beta-cells. Sulphonylureas bind to the sulphonylurea receptor in the pancreatic beta-cell plasma membrane, leading to closure of the ATP-sensitive potassium channel, thereby stimulating the release of insulin.
In healthy subjects, the time to reach maximal effect (minimum blood glucose concentrations) was approximately 2–3 hours after single oral doses of glimepiride. The effects of glimepiride on HbA1c, fasting plasma glucose, and post-prandial glucose have been assessed in clinical trials.
Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Hence, the combination of glimepiride, and metformin extended-release complement each other and provide better glycaemic control in the management of type 2 diabetes and probably helps in the prevention of diabetes associated macrovascular and microvascular complications.
Gliminus M1 – Strips of 10 Tablets
Gliminus M2 – Strips of 10 Tablets
Gliminus M4 – Strips of 10 Tablets

